Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib-Reference-Cited by-同舟云学术

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib

Published:2008-04-10 Issue:6 Volume:22 Page:1200-1206
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Hochhaus A,Baccarani M,Deininger M,Apperley J F,Lipton J H,Goldberg S L,Corm S,Shah N P,Cervantes F,Silver R T,Niederwieser D,Stone R M,Dombret H,Larson R A,Roy L,Hughes T,Müller M C,Ezzeddine R,Countouriotis A M,Kantarjian H M

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu200884.pdf

Reference20 articles.

1. Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM . The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172.

2. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.

3. Hochhaus A, Hughes T . Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 2004; 18: 641–656.

4. Hochhaus A, Druker B, Sawyers C, Guilhot F, Schiffer CA, Cortes J et al. Favorable long-term follow-up results over six years for response, survival and safety with imatinib mesylate therapy in chronic phase chronic myeloid leukemia post failure of interferon-alpha treatment. Blood 2008; 111: 1039–1043.

5. Druker BJ, Guilhot F, O’Brien S, Gathmann I, Kantarjian H, Gattermann N et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

Cited by 302 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computer-aided drug discovery of c-Abl kinase inhibitors from plant compounds against chronic myeloid leukemia;Journal of Biomolecular Structure and Dynamics;2024-03-22

2. Which Second-Line Tyrosine Kinase Inhibitor(s) for Chronic Myeloid Leukemia?;Current Treatment Options in Oncology;2023-04-29

3. Pharmacology of Small‐Molecule Anticancer Agents;Holland‐Frei Cancer Medicine;2022-10-21

4. Unilateral Interstitial Lung Disease with Contralateral Effusion: Unusual Case Report of Dasatinib Toxicity;Indian Journal of Medical and Paediatric Oncology;2022-02-15

5. Incidence, Prevalence, and Real-World Treatment Patterns in Chronic Myeloid Leukemia: Results from a Population-Representative German Claims Data Analysis;Oncology Research and Treatment;2022